Termicon

Quick links to important sections

Termicon

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Termicon

Termicon is a medicinal product identified by its active component, Terbinafine Hydrochloride, a highly effective synthetic compound used specifically as a single-ingredient therapy to eliminate fungal organisms.


Quick Facts: Termicon Identity

Property Description
Active ingredient Terbinafine Hydrochloride
Form Tablet, cream, solution, spray, and gel
Pharmacological class Antifungal Agent (Allylamine)
General Purpose Elimination of fungal infections
Origin Synthetic compound

Chemical Identity and Allylamine Classification

Termicon's identity is derived from its active ingredient, Terbinafine Hydrochloride, which is structurally classified within the pharmaceutical group known as the allylamine derivative class. This class of antifungals is recognized for its focused, high-efficacy intervention against fungi, offering a valuable distinction from other common antifungal medicines, such as the azoles. Terbinafine is an allylamine compound recognized for its fungicidal effects against dermatophytes. The compound has an established action against the most common types of skin fungi. Termicon's classification provides a targeted benefit in addressing various fungal infections and their causes.

Antifungal Action and Compound Nature

Termicon is officially designated as an Antifungal Agent (or Antimycotic), meaning its general therapeutic purpose is to destroy or inhibit the growth of pathogenic fungi. The unique feature of Terbinafine Hydrochloride is its nature as a fungicidal compound, which actively kills the fungal organism by disrupting its cellular structure, rather than simply suppressing its reproduction. The fungicidal, rather than fungistatic, nature of terbinafine against dermatophytes is clinically significant. This characteristic makes Termicon a crucial choice for eliminating the root cause of the infection and is typically employed to resolve superficial conditions, such as common athlete’s foot, caused by dermatophytes.

Available Forms for Systemic and Topical Use

As a versatile medicine, Termicon is manufactured in multiple dosage forms, including the tablet for systemic treatment and various topical preparations such as the cream, solution, spray, and gel. The compound remains a single-ingredient product across all forms. The availability of both the oral tablet, which is typically a prescription-only medicine (Rx), and the local topical forms, often sold over-the-counter (OTC), is strategically important. This allows treatment to be tailored to the infection's characteristics—oral administration ensures the medicine reaches deeply embedded infections, while topical forms are applied directly to the skin surface for localized treatment.

Regulatory References

  1. Terbinafine - StatPearls - NCBI Bookshelf
  2. Terbinafine: MedlinePlus Drug Information

What side effects are possible with Termicon?

Possible Side Effects and Safety Information for Termicon

This section summarizes the adverse reactions and safety information for Termicon as officially documented by authoritative government regulatory bodies (such as the FDA, EMA, Health Canada, or others). The safety profile is structured to categorize risks based on frequency, body system affected, and severity.


Adverse Reaction Scope

Safety Category Regulatory Status
Key Adverse Reaction Categories Information on specific adverse reactions and their categories is not explicitly available from current authoritative government regulatory sources.
Frequency Classification (Very Common / Common, etc.) Official frequency rates used in clinical trials (e.g., Common, Uncommon) are not defined in available regulatory documents.
System-Organ Classes Involved The body systems affected by adverse events (e.g., Gastrointestinal Disorders, Nervous System Disorders) are not cataloged in official regulatory texts.
Serious Adverse Reactions No specific serious or clinically significant adverse reactions have been formally documented or classified in the official regulatory texts reviewed.
Safety-Related Restrictions or Limitations Official contraindications or specific usage restrictions for certain populations or conditions are not explicitly stated in current regulatory documentation.

Safety Classifications (High-Level)

  • Regulatory Basis: Specific government regulatory documents (e.g., FDA label or EMA Summary of Product Characteristics) containing comprehensive safety and adverse reaction information for a pharmaceutical product named Termicon were not identified in the public domains of major health agencies.
  • Context-of-Use Safety Notes: No formal warnings or precautions regarding long-term use, co-administration with other substances, or specific patient monitoring requirements are detailed in available regulatory documents.

Resulting Safety Profile Structure

The structured approach adopted by health authorities provides a clear framework for assessing a medicine’s risks. The risk profile is typically defined by: 1) the classification of side effects by how often they occur (frequency), 2) the body systems they impact (System-Organ Class), and 3) formal statements on serious risks and restrictions.

As specific, officially documented data on Termicon is not available for review, its formal regulatory safety profile remains undefined according to this standard structure. Users should consult a qualified healthcare professional for safety information related to any product or substance.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the manifestations and required emergency actions in the event of an overdose with Terbinafine Hydrochloride. Overdose situations have been documented, including acute exposures up to 5 grams.

Documented Clinical Manifestations

The officially documented clinical manifestations of an overdose primarily involve gastrointestinal and neurological systems. These may include headache, dizziness, nausea, vomiting, and abdominal pain. Other manifestations listed in regulatory information include rash and frequent urination.

Mandatory Emergency Actions

The regulatory guidance strictly mandates that immediate medical attention must be sought for any suspected overdose. This requires immediately contacting a Poison Control Centre or Emergency Room. Urgent emergency services must be contacted immediately if severe, life-threatening clinical states are observed, such as collapse, seizure, trouble breathing, or being unable to be awakened.

Management and Antidote Status

Clinical management for an overdose is based on official protocols that prioritize the elimination of the drug from the body, primarily through the administration of activated charcoal. Subsequent treatment involves symptomatic supportive therapy tailored to the patient’s presentation. The regulatory documents confirm that there is no specific antidote available for Termicon overdose. Population-specific overdose considerations are not explicitly documented in the acute overdose sections of the official labels.

Therapeutic Uses of Termicon

Termicon (Terbinafine Hydrochloride) is an antifungal agent commonly used to manage the resulting symptomatic patterns across several significant dermatological domains, generally used in situations involving certain distressing symptoms caused by active fungal pathogens.

Oral Terbinafine is commonly used for managing conditions such as onychomycosis (fungal infection of the toenail or fingernail), Tinea Capitis (scalp ringworm), and other widespread dermatophyte infections like Athlete’s Foot, Jock Itch, and Ringworm. The medicine is applied in addressing symptoms related to inflammatory or irritative states like intense itching, scaling, and flaking of the skin, as well as nail discoloration and thickening.


Relief from Fungal Infection Symptoms

Termicon is relevant for easing symptom clusters that may become intense or disruptive, especially when the infection is chronic or where manifestations are deeply rooted. It is often used in settings where symptoms interfere with routine activities, generally assisting the patient in managing the overall symptomatic burden of persistent fungal disease. The therapeutic benefit may assist with the appearance of healthy tissue, which contributes to day-to-day comfort. The medication is commonly used to help patients manage challenging, persistent symptoms associated with dermatophyte infections.


Quick Fact: Relief for Persistent Symptoms
Symptom Type Dermal and Epidermal Discomfort (e.g., intense itching, scaling)
Condition Context Chronic or deeply seated infections (e.g., onychomycosis)
Benefit Focus Supports functional stability and helps ease the overall symptom load

Support for Severe or Recalcitrant Cases

Termicon is particularly relevant in clinical settings that involve acute or disruptive symptom patterns when infections are severe, extensive, or when conventional topical treatments have not been sufficient. It provides supportive relief when symptoms interfere with routine activities, contributing to improved comfort during symptomatic periods.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Termicon — official regulatory information

The official regulatory documents strictly define the population eligible for Termicon by establishing clear conditions for use and absolute exclusions. The drug is primarily intended for adults, but oral use is also established for pediatric patients aged 4 years and older (or weighing ge 12 kg) specifically for Tinea Capitis.


Eligibility Scope

  • Populations for whom use is contraindicated: Patients with a known hypersensitivity to terbinafine or any of the product’s components, and patients with chronic or active liver disease.
  • Populations for whom use is not recommended: Children under 4 years of age; individuals with severe renal impairment (Creatinine Clearance < 50 ml/min); and individuals who are pregnant or breastfeeding.

Eligibility-Context Constraints

Constraint Regulatory Status
Hepatic Function Contraindicated in chronic or active disease.
Renal Function Not recommended in severe impairment.
Pregnancy/Lactation Not recommended due to passage into breast milk.
Comorbidity Use requires caution in patients with Psoriasis or Lupus Erythematosus.

These regulatory statements dictate that use is either prohibited, not recommended, or requires documented caution for certain patient populations, ensuring adherence to the drug's official labeled use.

What should I know about interactions with other medicines?

Termicon, which contains both a nonsteroidal anti-inflammatory drug (NSAID) and a pain/fever reliever (acetaminophen), carries a risk of interaction with numerous other medications and substances. It is crucial to inform your doctor or pharmacist about all prescription drugs, over-the-counter medicines, and herbal supplements you are taking to prevent potentially serious complications.

Medications to Discuss with Your Healthcare Provider

  • Blood Thinners (Anticoagulants): Co-administering Termicon with medicines like warfarin or other anticoagulants significantly increases the risk of serious bleeding. Close monitoring and possible dosage adjustment of the anticoagulant are necessary.
  • Other NSAIDs or Acetaminophen-Containing Products: Combining Termicon with other NSAIDs (e.g., ibuprofen, naproxen, or low-dose aspirin) or with any product containing acetaminophen can increase the risk of side effects, including serious gastrointestinal bleeding or severe liver damage (hepatotoxicity).
  • Blood Pressure Medications: Termicon can reduce the effectiveness of certain blood pressure medicines, including ACE inhibitors, Angiotensin Receptor Blockers (ARBs), and diuretics (water pills). This combination may also increase the risk of kidney problems.
  • Other Agents: Tell your provider if you are taking medications for seizures, cholesterol-lowering agents, or specific antidepressants (SSRIs), as these can interact with Termicon. The combination of Termicon with alcohol increases the risk of liver damage and stomach bleeding; excessive consumption should be strictly avoided.

Mechanism of Action

Targeted Inhibition of Fungal Cell Sterol Synthesis

Termicon (Terbinafine Hydrochloride) acts by focusing on the fungal Squalene Epoxidase enzyme, a defined target enzyme within the ergosterol biosynthesis pathway. By acting as a non-competitive inhibitor, the drug blocks the enzymatic conversion of squalene, which immediately initiates a cascade of cellular failure specific to the fungal organism.


Dual-Action Disruption and Fungal Cell Death

The inhibition creates a dual cellular toxicity: a severe deficiency of ergosterol, which is essential for maintaining membrane structure, and a toxic accumulation of squalene inside the cell. This combined failure rapidly compromises the fungal cell membrane's integrity, resulting in the lysis and death of the fungal cell. This mechanism is classified as fungicidal and is supported by the drug's physical properties, which allow it to concentrate within keratinous tissues where the molecule remains localized in these structures.

Dosage and Administration Information

Termicon (Terbinafine Hydrochloride) is administered via two primary, officially approved routes: oral for systemic treatment (using the 250 mg tablet or oral granules) and topical for localized surface treatment (using the 1% cream, solution, or spray). Administration is governed by fixed, indication-specific schedules defined by regulatory authorities.

Oral Dosing and Duration

For systemic use, the standard adult dose for all approved indications is 250 mg once daily.

Indication (Adults) Daily Dose Duration Pattern (Typically Sufficient)
Onychomycosis (Fingernail) 250 mg 6 weeks
Onychomycosis (Toenail) 250 mg 12 weeks
Tinea Infections (e.g., Pedis, Corporis) 250 mg 2 to 6 weeks

Administration Requirements

  • Timing: Oral tablets can be taken with or without food; however, consistency is advised (preferably taken at the same time each day).
  • Pediatric Use: Oral granules are weight-band dosed (125 mg to 250 mg daily) and must be taken with food. Granules must be sprinkled on soft, non-acidic food (e.g., pudding, mashed potatoes) and swallowed without chewing.
  • Special Considerations: The use of oral Termicon is not recommended in patients with chronic or active hepatic disease. For onychomycosis, appropriate laboratory testing must be obtained to confirm diagnosis prior to initiating systemic treatment.
  • Duration Note: The full clinical effect for onychomycosis is observed several months after cessation of therapy, corresponding to the time required for healthy nail outgrowth.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Termicon

The research for Termicon (Terbinafine Hydrochloride) is based on the clinical evidence that regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), rely upon. This overview summarizes the structure and scope of the clinical evidence without offering any clinical guidance, treatment advice, or details on the mechanism of action.


Evidence for Use in Onychomycosis (Fungal Nail Infection)

Research was conducted to explore the use of oral Termicon in treating onychomycosis (fungal nail infection). Studies were designed to measure mycological endpoint (fungal clearance) and clinical endpoint (resolution of physical signs), often tracked as a combined complete cure measurement. Follow-up periods typically spanned 6 months to 1 year.


Evidence for Use in Widespread Dermatophyte Infections

The evidence base is based on Randomized Controlled Trials that investigated both oral and various topical preparations for common fungal skin conditions like athlete's foot and ringworm. Studies monitored fungal clearance measurement and the resolution of physical discomfort (such as itching and scaling) over short-term intervals. Research provides insight into short-term changes but notes challenges in confirming real-world patient adherence to topical schedules.


Evidence for Use in Tinea Capitis (Scalp Ringworm)

Studies explored the question of oral Termicon for Tinea Capitis (scalp ringworm), focusing specifically on the pediatric population (children). Research monitored the mycological endpoint and changes in physical signs. Research contributes to the broader evidence landscape by describing short-term patterns of response over the typical treatment course.


What the Research Indicates is Still Unknown

Research notes that follow-up durations were short in many studies, meaning the long-term history of the condition post-treatment is not fully characterized. Findings indicate that long-term effects are not fully established beyond the first year post-treatment in all cases. Data for certain specific groups, such as adults with Tinea Capitis, remain insufficient. Furthermore, comparative evidence is lacking for certain head-to-head trials against newer antifungal compounds.

Key Studies & References

  1. Terbinafine for onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium) - FDA Prescribing Information
  2. Terbinafine Compared to Griseofulvin in Children With Tinea Capitis (RCT Design/Endpoints)
  3. Terbinafine - StatPearls - NCBI Bookshelf (Review of Indications, Efficacy, and Population Use)

Frequently Asked Questions (FAQ)

Common questions about Termicon (FAQ)


Q: How does Termicon compare to older, established medicines for the same condition (without asking for advice)?

A: Termicon's active ingredient, Terbinafine, is classified by regulatory documents as an allylamine antifungal agent. This class of medicine's action is officially defined as fungicidal against dermatophytes, meaning it is intended to actively kill the fungal organism. This feature is a key characteristic that distinguishes it from some other antifungal drug classes, such as the azoles, which may primarily work by limiting fungal growth (fungistatic).


Q: Are there any concerns about taking Termicon while pregnant or breastfeeding?

A: Official product information advises caution regarding use during pregnancy due to limited clinical experience in pregnant women, and official documents state that use is not recommended unless a healthcare provider determines the potential benefit to the patient outweighs the risk. If a mother is receiving oral treatment with Termicon, regulatory documents state that she should not breastfeed, as the drug is known to be excreted in breast milk.


Q: How quickly does Termicon typically start to work or show its effects?

A: Official product information notes the drug concentrates in the skin, hair, and nails following oral administration. However, the time it takes to see the full clinical results can vary greatly by the type of infection. For fungal nail infections (onychomycosis), the complete effects are typically observed several months after the treatment course is finished, corresponding to the time needed for the healthy nail to grow out.


Q: Will I need regular blood tests or monitoring while taking Termicon?

A: Official labeling indicates that periodic monitoring of liver function tests is generally necessary (for example, after the first 4 to 6 weeks of treatment). For certain patient populations, such as those with known or suspected immunodeficiency, monitoring of complete blood counts (a routine blood test) may be considered if the medicine is taken for more than six weeks.


Q: Does Termicon interact with hormonal contraceptives or birth control?

A: Studies suggest that Termicon has a low likelihood of significantly changing the way the body processes most drugs, including oral contraceptives. While this interaction potential is considered negligible, regulatory documents mention that cases of menstrual disturbance (such as irregular cycles or breakthrough bleeding) have been reported, although the rate is similar to that observed when oral contraceptives are taken alone.


Q: Can Termicon be taken if a person is fasting or on a restricted diet?

A: The official administration advice varies depending on the form of the drug. Termicon oral tablets can generally be taken with or without food. However, the oral granules, which are typically used for pediatric patients, must be mixed with and swallowed with food for proper use.


Q: Can Termicon cause weight gain or weight loss?

A: Official regulatory documents have reported weight loss as an uncommon side effect. This may sometimes occur because the drug can cause a change in the sense of taste, which can potentially lead to a decrease in food intake. Weight gain is not cited as a commonly reported side effect in the official product information.


Q: Are the side effects of Termicon generally considered mild or serious?

A: According to official patient information, the side effects are generally described as being mild or moderate and are typically not long-lasting. However, all regulatory bodies track rare but serious adverse effects that have been reported in post-marketing settings, including severe liver problems and severe skin reactions.


Q: How long do the common side effects of Termicon typically last?

A: The duration of side effects is not specifically defined for every event. However, a common side effect like taste disturbance (dysgeusia) usually resolves within several weeks after stopping the medication. Isolated reports of a longer duration for taste disturbance have been noted in regulatory records.


Q: Is it normal to feel a specific side effect (e.g., fatigue, dizziness) in the first week of taking Termicon?

A: Official safety data lists fatigue as a common side effect and dizziness as an uncommon or very rare side effect. While regulatory documents list the frequency of these potential effects, they do not specify when during treatment they are expected to occur or whether they are normal to experience within the first week.


Q: Can Termicon affect blood pressure or heart rate?

A: Post-marketing reports have included the rare adverse event of vasculitis (inflammation of blood vessels) and fast heartbeat. However, the regulatory label does not characterize the drug as having a pervasive effect on blood pressure.


Q: Is Termicon safe to use for patients over the age of 65?

A: Studies reviewed by regulatory bodies have not demonstrated any geriatric-specific problems that would limit the drug's usefulness in this age group. Official information does note that elderly patients are more likely to have pre-existing age-related conditions affecting the liver, kidneys, or heart, which means that individual caution is noted.


Q: What is the expected length of time for a person to take Termicon?

A: The total duration of therapy is defined by the specific infection being treated. For fungal fingernail infections, the typical duration is 6 weeks, while for toenail infections, the typical duration is 12 weeks. Shorter courses, generally between 2 to 6 weeks, are typical for many skin infections.


Q: What happens if I miss a single dose of Termicon?

A: Official patient information states that if a dose is missed, a person can take it as soon as remembered, unless it is almost time for the next scheduled dose. If that is the case, the missed dose should be skipped, and the person should resume their regular schedule. Official patient information also states not to take two doses to compensate for the one that was missed.


Q: Does Termicon cause sensitivity to sun exposure?

A: Yes, regulatory warnings note that Termicon can cause photosensitivity reactions. Official guidance advises patients to take precautions such as minimizing exposure to both natural and artificial sunlight (like tanning beds) and to use appropriate protective measures, such as sunscreen and protective clothing, if sun exposure cannot be avoided.


Q: Can Termicon cause changes in sleep patterns (like insomnia or drowsiness)?

A: Safety data indicates that trouble with sleeping (insomnia) is listed as a less common side effect. Although drowsiness or excessive sleepiness is not frequently cited, related effects like dizziness have been reported in clinical and post-marketing data.


Q: Can I drive or operate machinery while taking Termicon?

A: Regulatory documents state that no specific studies on the effect of the drug on driving ability have been performed. However, because some people may experience undesirable effects such as dizziness, official guidance states that people who experience such effects should refrain from driving or operating machinery until they know how the medicine affects them.


Q: What are the most serious but rare side effects listed for Termicon?

A: Official labeling reports that very rare but serious side effects include severe liver problems (some of which have required liver transplants or resulted in death), severe skin reactions (such as Stevens-Johnson syndrome), and certain blood disorders (including agranulocytosis and neutropenia).


Q: What other agents should I tell my provider about, besides blood thinners and blood pressure medications?

A: The official interaction documents list several drug classes that should be discussed with a provider. Examples of other medications that may interact with Termicon include certain antidepressants (especially SSRIs), beta-blockers, certain antiarrhythmics, and specific immune-suppressing agents like cyclosporine. Additionally, the acid reducer cimetidine and the anti-tuberculosis agent rifampicin may also require discussion.


Q: Does Termicon have any known effects on mental clarity or concentration?

A: Clinical and post-marketing data have reported some side effects that may affect mental clarity. These effects include trouble concentrating, anxiety, depressive symptoms, and dizziness. Individuals should be aware of these potential effects.

How should Termicon be stored and disposed of?

How to Store and Dispose of Termicon

Termicon (Terbinafine Hydrochloride) must be stored and disposed of according to official regulatory labeling to maintain stability and safety.

Official Storage Conditions

Tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be protected from light and moisture and kept in the original, tightly closed container.

Topical Preparations should be stored below 25 C and must not be frozen. Any unused cream must be discarded 28 days after first opening the tube.

Child Safety and Disposal

All forms of Termicon must be kept strictly out of the sight and reach of children. For disposal, do not flush the medicine down the toilet or throw it away in household trash. Unused or expired medication should be returned to a medicine take-back program or pharmacy for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Termicon found in:

A-Z Index: